

d his *STN Search History*

(FILE 'HOME' ENTERED AT 08:07:25 ON 04 MAR 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGUPDATES, ...' ENTERED AT 08:07:55 ON 04 MAR 2003

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 08:08:28 ON 04 MAR 2003

SEA ORAL (S) (DELIVER### COMPOSITION ADMINIS##### DOS###) AND

-----  
0\* FILE FEDRIP

L1 QUE ORAL (S) (DELIVER### COMPOSITION ADMINIS##### DOS###) AND

-----  
SEA ORAL (P) (DELIVER### COMPOSITION ADMINIS##### DOS###) AND

-----  
0\* FILE ADISNEWS  
0\* FILE BIOCOMMERCE  
0\* FILE BIOTECHABS  
0\* FILE BIOTECHDS  
0\* FILE BIOTECHNO  
0\* FILE CEABA-VTB  
0\* FILE CIN  
0\* FILE ESBIOBASE  
0\* FILE FEDRIP  
0\* FILE FOMAD  
0\* FILE FOREGE  
0\* FILE FROSTI  
0\* FILE FSTA  
0\* FILE KOSMET  
0\* FILE MEDICONF  
0\* FILE NTIS  
0\* FILE NUTRACEUT  
0\* FILE PASCAL  
0\* FILE PHARMAML  
0\* FILE BABS  
0\* FILE CBNB

L2 QUE ORAL (P) (DELIVER### COMPOSITION ADMINIS##### DOS###) AND

-----  
SEA (ANTIMICROB### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAX

-----  
4\* FILE ADISCTI  
2\* FILE ADISINSIGHT  
1\* FILE ADISNEWS  
4\* FILE AGRICOLA  
0\* FILE ANABSTR  
0\* FILE AQUASCI  
2\* FILE BIOBUSINESS  
1\* FILE BIOCOMMERCE  
45 FILE BIOSIS  
33\* FILE BIOTECHABS  
33\* FILE BIOTECHDS  
21 FILE BIOTECHNO  
6\* FILE CABA  
11 FILE CANCERLIT

772 FILE CAPLUS  
5\* FILE CEABA-VTB  
17\* FILE CEN  
2 FILE CIN  
0\* FILE CONFSCI  
0\* FILE CROPB  
18\* FILE CROPU  
31\* FILE DDFB  
98\* FILE DDFU  
0\* FILE DGENE  
31\* FILE DRUGB  
0\* FILE DRUGLAUNCH  
0\* FILE DRUGMONOG2  
1\* FILE DRUGNL  
138\* FILE DRUGU  
1\* FILE DRUGUPDATES  
0\* FILE EMBAL  
62 FILE EMBASE  
6\* FILE ESBIOBASE  
7\* FILE FEDRIP  
0\* FILE FOMAD  
0\* FILE FOREGE  
10\* FILE FROSTI  
4 FILE FSTA  
1 FILE GENBANK  
0\* FILE HEALSAFE  
523\* FILE IFIPAT  
108\* FILE JICST-EPLUS  
7\* FILE KOSMET  
7\* FILE LIFESCI  
84 FILE MEDLINE  
1\* FILE NIOSHTIC  
0\* FILE NUTRACEUT  
0\* FILE OCEAN  
41\* FILE PASCAL  
4\* FILE PHARMAML  
21 FILE PHIN  
178\* FILE PROMT  
40 FILE SCISEARCH  
0\* FILE SYNTHLINE  
167 FILE TOXCENTER  
27057 FILE USPATFULL  
564 FILE USPAT2  
0\* FILE VETB  
11\* FILE VETU  
582 FILE WPIDS  
582 FILE WPINDEX  
2\* FILE BABS  
10\* FILE CBNB  
10\* FILE DIOGENES  
110\* FILE INVESTTEXT  
1\* FILE IPA  
2 FILE NAPRALERT  
L3 QUE (ANTIMICROB#### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXO  
-----

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, BIOTECHNO, SCISEARCH' ENTERED AT  
08:27:14 ON 04 MAR 2003

L4 1024 S L3  
L5 156 S (ANTIMICROB#### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXON  
L6 1 S L4 AND L5

L7           0 S L4 AND (CEPHALOSPORIN OR CEFTRIAXONE) AND (METAL (S) CATION  
L8           41 S L4 AND (CEPHALOSPORIN OR CEFTRIAXONE) AND (METAL OR ZINC OR  
L9           39 DUP REM L8 (2 DUPLICATES REMOVED)  
L10          40 S L4 AND (METAL (S) CATION##)  
L11          36 DUP REM L10 (4 DUPLICATES REMOVED)  
L12          36 S L11 NOT L9

FILE 'STNGUIDE' ENTERED AT 09:12:37 ON 04 MAR 2003

L1 QUE ORAL (S) (DELIVER### COMPOSITION ADMINIS##### DOS###) AND (ANTIMICRO  
B### ANTIBIOTIC CEPHALOSPORIN CEFTRIAXONE)  
L2 QUE ORAL (P) (DELIVER### COMPOSITION ADMINIS##### DOS###) AND (ANTIMICRO  
B### ANTIBIOTIC CEPHALOSPORIN CEFTRIAXONE)  
L3 QUE (ANTIMICROB### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXONE) AND (?P  
OLYMER OR CARRAGEENAN OR CHITOSAN OR PEG OR POLYETHYLENE OR LIPOSOM##  
OR BIOPOLYMER) AND (METAL (A) CATION OR METAL (S) CATION## OR ZINC OR  
CALCIUM)  
L4 1024 L3  
L5 156 (ANTIMICROB### OR ANTIBIOTIC OR CEPHALOSPORIN OR CEFTRIAXONE)  
AND (ABSOR### WITH ENHANC###)  
L6 1 L4 AND L5  
L7 0 L4 AND (CEPHALOSPORIN OR CEFTRIAXONE) AND (METAL (S) CATION##)  
L8 41 L4 AND (CEPHALOSPORIN OR CEFTRIAXONE) AND (METAL OR ZINC OR  
CALCIUM)  
L9 39 DUP REM L8 (2 DUPLICATES REMOVED)

L9 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI An extended release pharmaceutical composition containing  $\beta$ -lactam  
antibiotics with improved therapeutic efficacy  
SO PCT Int. Appl., 16 pp.  
CODEN: PIXXD2  
IN Pendyala, Rama Rao; Khadgapathi, Podili; Nannapaneni, Venkaiah Chowdary;  
Pavuluri, Venkateswara Rao  
L9 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Compositions and methods to improve the oral absorption of  
antimicrobial agents  
SO PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
IN Choi, Seung-Ho; Lee, Jeoung-Soo; Keith, Dennis  
L9 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Liquid composition of a biodegradable block copolymer for drug  
delivery system  
SO PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
IN Seo, Min-hyo; Choi, In-ja  
L9 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Solid carriers for improved delivery of active ingredients in  
pharmaceutical compositions  
SO PCT Int. Appl., 107 pp.  
CODEN: PIXXD2  
IN Patel, Manesh V.; Chen, Feng-jing  
L9 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Oil-in-water emulsion compositions for polyfunctional active ingredients  
SO PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
IN Chen, Feng-jing; Patel, Mahesh V  
L9 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Therapeutic treatment and prevention of infections with a bioactive  
materials encapsulated within a biodegradable-biocompatible polymeric  
matrix  
SO U.S., 141 pp., Cont.-in-part of U.S. Ser. No. 590,973, abandoned.  
CODEN: USXXAM  
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot;  
Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Jarboe,  
Daniel L.; Cassels, Frederick; Brown, William; Thies, Curt; Tice, Thomas  
R.; Roberts, F. Donald; Friden, Phil  
L9 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Complexes to improve oral absorption of poorly absorbable  
antibiotics  
SO U.S., 9 pp.  
CODEN: USXXAM  
IN Choi, Seung-ho; Lee, Jeoung-soo  
L9 ANSWER 20 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
TI The possibility of clinical use of oral formulation of **Ceftriaxone**,  
the third generation **cephalosporin**.  
SO Abstracts of the General Meeting of the American Society for Microbiology,  
(2001) Vol. 101, pp. 31. <http://www.asmusa.org/mtgsrc/generalmeeting.htm>.  
print.  
Meeting Info.: 101st General Meeting of the American Society for  
Microbiology Orlando, FL, USA May 20-24, 2001  
ISSN: 1060-2011.  
AU Lee, J. (1); Kim, S.; Choi, S.  
L9 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Production of **cephalosporin C** by immobilized cells of  
Cephalosporium acremonium  
SO Indian Journal of Experimental Biology (2000), 38(11), 1134-1137  
CODEN: IJEBAA; ISSN: 0019-5189

AU Ellaiah, P.; Chand, G. Murali; Srinivasulu, B.; Pardhasaradhi, S. V.  
L9 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Method for stabilizing active substances for controlled release pharmaceutical formulation  
SO PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
IN Kofler, Bojan; Rebic, Ljubomira Barbara; Sirca, Judita; Venturini, Peter  
L9 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Preparation of microsphere drug delivery systems  
SO PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
IN Wu, Xiao Yu; Liu, Zhi  
L9 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix  
SO PCT Int. Appl., 363 pp.  
CODEN: PIXXD2  
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil  
L9 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Pharmaceutical composition for rapid suspension in aqueous media  
SO PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
IN Calanchi, Massimo Maria; Marconi, Marco Giuseppe Raffaele; Mapelli, Luigi Giovanni  
L9 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Pharmaceutical preparation comprising coated capsules or tablets containing a **liposome** powder encapsulating a drug  
SO Eur. Pat. Appl., 10 pp.  
CODEN: EPXXDW  
IN Garces Garces, Josep; Bonilla Munoz, Angel; Parente Duena, Antonio  
L9 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Controlled-release bioadhesive pharmaceutical compositions containing vinyl acetate-vinylpyrrolidone **copolymer**  
SO Eur. Pat. Appl., 7 pp.  
CODEN: EPXXDW  
IN Rault, Isabelle; Pichon, Gerald  
L9 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Compatibility of doxorubicin hydrochloride **liposome** injection with selected other drugs during simulated Y-site administration  
SO American Journal of Health-System Pharmacy (1997), 54(23), 2708-2713  
CODEN: AHSPEK; ISSN: 1079-2082  
AU Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.  
L9 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence  
SO Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
IN Esposito, Pierandrea; Carli, Fabio  
L9 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2003 ACS  
TI Controlled-release microparticle periodontal disease treatment system  
SO Eur. Pat. Appl., 16 pp.  
CODEN: EPXXDW  
IN Baker, Richard W.  
L9 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2003 ACS

TI Dispenser for the sustained release of pharmaceuticals  
SO Ger. Offen., 15 pp.  
CODEN: GWXXBX  
IN Eckenhoff, James B.; Cortese, Richard; Landrau, Felix A.

L9 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1992:28178 CAPLUS

DN 116:28178

TI Controlled-release microparticle periodontal disease treatment system

IN Baker, Richard W.

PA Pharmetrix Corp., USA

SO Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 451390	A1	19911016	EP 1990-303916	19900411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2012665	AA	19910921	CA 1990-2012665	19900321
	AU 629316	B2	19921001	AU 1990-52166	19900326
	AU 9052166	A1	19911003		
	JP 04005227	A2	19920109	JP 1990-101545	19900417

PRAI EP 1990-303916 19900411

AB A controlled-release drug delivery system (for prophylactics, antiseptics, **antibiotics**, etc.) is provided for placement in the periodontal pocket, gingival sulcus, tooth socket, wound, or other cavity within the mouth. The system incorporates drug-contg. microparticles in a fluid carrier medium and is effective in the environment of use for .1toreq.30 days. Polycarbonate microparticles contg. 18-35 wt.% tetracycline, 50-500 .mu.m in size, were capable of delivering tetracycline in a sustained fashion for periods of .apprx.25 h. Among the systems described are diffusion-controlled systems, erosion-controlled systems, a leaching-controlled system, and a combined diffusion/erosion-controlled system.

L9 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1993:154582 CAPLUS

DN 118:154582

TI Solid pharmaceutical compositions for oral administration with prolonged gastric residence

IN Esposito, Pierandrea; Carli, Fabio

PA Vectorpharma International S.p.A., Italy

SO Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526862	A1	19930210	EP 1992-113187	19920803
	EP 526862	B1	19960214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 134134	E	19960215	AT 1992-113187	19920803
	ES 2086029	T3	19960616	ES 1992-113187	19920803

PRAI IT 1991-MI2212 19910806

AB The title compns. comprise an active ingredient characterized by erratic gastrointestinal absorption, a high d. inorg. substance, such as BaSO4, Fe, Mg trisilicate, and a bioadhesive **polymer**, such as cellulose ethers and acrylate copolymers. For example, a tablet was formulated contg. nifedipine with micronized crosslinked PVP (1:5) 240, BaSO4 235, Methocel A4C 155, Aerosil 200 5, xanthan gum 30, galactomannan 30, and Mg stearate 5 mg.

L9 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1997:795285 CAPLUS

DN 128:110395

TI Compatibility of doxorubicin hydrochloride **liposome** injection with selected other drugs during simulated Y-site administration  
AU Trissel, Lawrence A.; Gilbert, Doward L.; Martinez, Juan F.  
CS Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA  
SO American Journal of Health-System Pharmacy (1997), 54(23), 2708-2713  
CODEN: AHSPEK; ISSN: 1079-2082  
PB American Society of Health-System Pharmacists  
DT Journal  
LA English  
AB The compatibility of doxorubicin hydrochloride **liposome** injection with selected other drugs during simulated Y-site administration was studied. Five milliliters of doxorubicin hydrochloride **liposome** injection 0.4 mg/mL in 5% dextrose injection was combined with 5 mL of each of 82 other drugs in 5% dextrose injection or, if necessary to avoid incompatibilities with the diluent, 0.9% sodium chloride injection. The combinations were examined with the unaided eye in fluorescent light and in high-intensity monodirectional light to enhance visualization of small particles and low-level turbidity. The turbidity of each combination was measured as well. Particle sizing and counting were performed on selected combinations. Evaluations were performed initially and at one and four hours. All combinations were stored at room temp. (.apprx.23 .degree.C). Most of the test drugs were compatible with doxorubicin hydrochloride **liposome** injection during the four-hour observation period. However, practitioners should be cautious in administering any drug simultaneously with doxorubicin hydrochloride **liposome** injection until the integrity of the **liposomes** can be verified. Eighteen drugs exhibited unacceptable increases or decreases in measured turbidity or particulate formation within four hours. During simulated Y-site administration, doxorubicin hydrochloride 0.4 mg/mL (as the **liposomal** injection) in 5% dextrose injection was compatible with 64 of 82 other drugs for four hours at .apprx.23 .degree.C and was incompatible with 18 of the test drugs.

L9 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1998:742255 CAPLUS

DN 130:17234

TI Preparation of microsphere drug delivery systems

IN Wu, Xiao Yu; Liu, Zhi

PA Can.

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850018	A1	19981112	WO 1998-CA419	19980506
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9872019	A1	19981127	AU 1998-72019	19980506
PRAI	US 1997-45710P	P	19970506		
	WO 1998-CA419	W	19980506		
AB	A drug delivery compn. comprising microspheres contg. at least one chemotherapeutic agent and at least 1 chemosensitizer wherein the				

microspheres have a biodegradable **polymer** matrix with functional groups which assoc. with the chemotherapeutic agent and chemosensitizer is described. Carboxymethyl dextran microspheres were prepd. and mixed with 1% verapamil or doxorubicin aq. soln. The microspheres showed sustained drug release.

L9 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1998:527193 CAPLUS

DN 129:166193

TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix

IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil

PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.

SO PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

US 6309669 B1 20011030 US 1997-789734 19970127

AU 9863175 A1 19980818 AU 1998-63175 19980127

PRAI US 1997-789734 A 19970127

US 1984-590308 B1 19840316

US 1992-867301 A2 19920410

US 1995-446148 A2 19950522

US 1995-446149 B2 19950522

US 1996-590973 B2 19960124

WO 1998-US1556 W 19980127

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aq. physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) **copolymer**, which may contain a pharmaceutically acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

L9 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1998:501150 CAPLUS

DN 129:166204

TI Pharmaceutical preparation comprising coated capsules or tablets containing a **liposome** powder encapsulating a drug

IN Garces Garces, Josep; Bonilla Munoz, Angel; Parente Duena, Antonio

PA Lipotec, S.A., Spain

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	EP 855179	A2	19980729	EP 1997-500231	19971231
	EP 855179	A3	19990324		
	EP 855179	B1	20021113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ES 2130056	A1	19990616	ES 1997-73	19970116
	ES 2130056	B1	20000201		
	JP 10203964	A2	19980804	JP 1998-5926	19980114
PRAI	ES 1997-73	A	19970116		
AB	A new pharmaceutical prepn. to improve the oral bioavailability of difficult-to-absorb drugs comprising capsules or tablets coated with enteric material contg. a freeze-dried or evapd. <b>liposome</b> powder incorporating a drug of pharmacol. benefit. A mixt. of 800 mg cholesterol and 800 mg hydrogenated lecithin was added to 1.25 g nimesulide (I) and heated at 60.degree. to obtain a suspension of <b>liposomes</b> incorporating I. The resulting <b>liposome</b> suspension was frozen and freeze-dried to obtain a freeze-dried prepn. which was placed in hard gelatin capsules (114 mg in each capsule). The resulting capsules were coated with Eudragit L by repeated immersion in a soln. of enteric <b>polymer</b> in isopropanol and subsequent drying in a current of air. The blood level of I in volunteers after 5 h was 7.31 as compared with 2.69 .mu.g/mL.				
L9	<u>ANSWER 17 OF 39</u> CAPLUS COPYRIGHT 2003 ACS				
AN	2001:792223 CAPLUS				
DN	135:348878				
TI	Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix				
IN	Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Jarboe, Daniel L.; Cassels, Frederick; Brown, William; Thies, Curt; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil				
PA	United States of America as Represented by the Secretary of the Army, USA				
SO	U.S., 141 pp., Cont.-in-part of U.S. Ser. No. 590,973, abandoned.				
	CODEN: USXXAM				
DT	Patent				
LA	English				
FAN.CNT 12					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6309669	B1	20011030	US 1997-789734	19970127
	US 5417986	A	19950523	US 1992-867301	19920410
	US 6410056	B1	20020625	US 1995-446148	19950522
	US 6447796	B1	20020910	US 1997-920326	19970821
	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	US 1990-493597	B2	19900315		

US 1990-521945	B2	19900511
US 1991-690485	B2	19910424
US 1991-805721	B2	19911121
US 1994-209350	B2	19940107
US 1994-242960	A2	19940516
US 1996-675895	A2	19960705
US 1996-698896	A2	19960816
US 1997-789734	A2	19970127
WO 1998-US1556	W	19980127

AB Novel burst-free, sustained-release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aq. physiol. environment are disclosed. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) **copolymer**, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99. Ampicillin microcapsules effectively prevented infection in 73% of rats whose wound were inoculated with ampicillin-resistant strains of *Staphilococcus aureus*, while systemic ampicillin failed in 100% of animals.

L9 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2001:449182 CAPLUS

DN 135:51066

TI Complexes to improve oral absorption of poorly absorbable **antibiotics**

IN Choi, Seung-ho; Lee, Jeoung-soo

PA International Health Management Associates, Inc., USA

SO U.S., 9 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6248360	B1	20010619	US 2000-598089	20000621
	WO 2001097851	A2	20011227	WO 2001-US19625	20010618
	WO 2001097851	A3	20020516		
				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
				RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	

PRAI US 2000-598089 A 20000621  
 US 2001-829405 A 20010409  
 US 2001-283976P P 20010416

AB The present invention provides compns. and methods for increasing absorption of poorly absorbable **antibiotics**, particularly third generation **cephalosporin antibiotics**, in oral dosage solid and/or suspension forms. Specifically, the compn. is comprised of a **biopolymer** that is preferably swellable and/or mucoadhesive, a poorly absorbable **antibiotic**, and a cationic binding agent contained within the **biopolymer** such that the binding agent is tonically bound or complexed to at least 1 member selected from the group consisting of the **biopolymer** and the **antibiotic**. A **ceftriaxone-carrageenan-calcium** complex was prep'd. by the treatment of the **antibiotic** with **calcium**

and **carageenan**. The plasma drug concn. from the complex was greater than that obtained by administering the **antibiotic** in an uncomplexed state.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 39 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2002:176236 BIOSIS

DN PREV200200176236

TI The possibility of clinical use of oral formulation of **Ceftriaxone**, the third generation **cephalosporin**.

AU Lee, J. (1); Kim, S.; Choi, S.

CS (1) University of Utah, Salt Lake City, UT USA

SO Abstracts of the General Meeting of the American Society for Microbiology, (2001) Vol. 101, pp. 31. <http://www.asmusa.org/mtgsrc/generalmeeting.htm>. print.

Meeting Info.: 101st General Meeting of the American Society for Microbiology Orlando, FL, USA May 20-24, 2001

ISSN: 1060-2011.

DT Conference

LA English

AB Background: In order to evaluate the possibility of oral administration of **Ceftriaxone** (CTX) which is a poorly absorbed broad-spectrum third generation **cephalosporin** through the intestinal membrane, we prepared various oral formulations of CTX by combining CTX with mucoadhesive polymers using **metal** ion as binding agent.

Mucoadhesive polymers that bind to the gastric mucin or epithelial cell surface are useful in drug delivery for the purpose of (a) retaining dosage forms in the GI tract and (b) increasing the intimacy and duration of contact of drug with the absorbing membrane. The bioavailability of oral formulations of CTX was investigated from each formulation. Method: Various oral formulations of CTX with mucoadhesive **polymer** were prepared by changing the ratio of **polymer** and **calcium** ion. **Carageenan** (CG) and pectin (PT) was employed as mucoadhesive polymers. The formulations (40mg CTX equivalents/kg) were administered into the duodenum of male Sprague-Dawley rats (n=5) in order to bypass the stomach with capmul. Blood samples were taken at predetermined time intervals and CTX was bioassayed and analyzed by HPLC.

Result: The i.v. and i.d. blood data were analyzed by Pharsight Winnonlin ver 3.0. In case of using CG, the bioavailability (%BA) value of CTX1-Ca0.2-CG4, CTX1-Ca0.5-CG4, CTX1-Ca1-CG4 and CTX1CG4 was 36.9, 6.1, 0, and 10.0%, respectively. In case of using PT, CTX1-Ca0.2-PT4, CTX1-Ca0.4-PT4, CTX1-Ca0.2-PT8, and CTX1PT4 was 40.6, 24.2, 13.8, and 29.9%, respectively. Bioavailability of the i.d. CTX (control) was 9.4%.

Enhancing ratio was calculated from AUC for CTX1-Ca0.2-CG4, CTX1-Ca0.2-PT4 which were the best oral formulations of CTX against i.d. CTX. Value was 3.92; and 4.32, respectively. Conclusion: As with in vivo result, CTX1-Ca0.2-CG4 and CTX1-Ca0.2-PT4 significantly improved gastrointestinal absorption of CTX. Therefore these oral formulations of CTX are promising candidates for clinical use of CTX and other third generation **cephalosporins**

L9 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 2001:65840 CAPLUS

DN 134:325248

TI Production of **cephalosporin C** by immobilized cells of **Cephalosporium acremonium**

AU Ellaiah, P.; Chand, G. Murali; Srinivasulu, B.; Pardhasaradhi, S. V.

CS Pharmaceutical Biotechnology Division, Department of Pharmaceutical Sciences, Andhra University, Visakhapatnam, 530 003, India

SO Indian Journal of Experimental Biology (2000), 38(11), 1134-1137  
CODEN: IJEBAA; ISSN: 0019-5189

PB National Institute of Science Communication, CSIR

DT Journal

LA English

AB Cephalosporium acremonium ATCC 48272 cells were immobilized on various adsorbents and in various entrapment matrixes. The influence of the incubation period, the best immobilization technique and the optimum concns. of the selected matrixes were investigated. From the results of the repeated batch fermn. in shake flasks, a good level of **antibiotic** was maintained for a period of about 19 days using 4% **calcium alginate** and 1% glass wool as entrapment and adsorbent supports, resp.

L9 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2003 ACS

AN 1987:541112 CAPLUS

DN 107:141112

TI Dispenser for the sustained release of pharmaceuticals

IN Eckenhoff, James B.; Cortese, Richard; Landrau, Felix A.

PA Alza Corp., USA

SO Ger. Offen., 15 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3626103	A1	19870212	DE 1986-3626103	19860801
	DE 3626103	C2	19980219		
	US 4684524	A	19870804	US 1985-763493	19850808
	ES 556303	A1	19871016	ES 1986-556303	19860619
	ES 556375	A1	19880401	ES 1986-556375	19860620
	GB 2178659	A1	19870218	GB 1986-18350	19860728
	GB 2178659	B2	19890913		
	JP 62039518	A2	19870220	JP 1986-178598	19860729
	JP 08018972	B4	19960228		
	GB 2178660	A1	19870218	GB 1986-18568	19860730
	GB 2178660	B2	19890906		
	DE 3625915	A1	19870219	DE 1986-3625915	19860731
	DE 3625915	C2	19970424		
	JP 62039519	A2	19870220	JP 1986-181189	19860731
	JP 07059497	B4	19950628		
	AU 8660780	A1	19870212	AU 1986-60780	19860801
	AU 590308	B2	19891102		
	FR 2585950	A1	19870213	FR 1986-11370	19860806
	FR 2585950	B1	19890303		
	FR 2585951	A1	19870213	FR 1986-11371	19860806
	FR 2585951	B1	19890303		
	BR 8603756	A	19870310	BR 1986-3756	19860806
	ZA 8605914	A	19870429	ZA 1986-5914	19860806
	CA 1265966	A1	19900220	CA 1986-515469	19860807
	ZA 8605982	A	19870429	ZA 1986-5982	19860808
	AU 654515	B2	19941110	AU 1991-89738	19911216
PRAI	US 1985-763493	A	19850808		
	US 1984-590778	A2	19840319		
	US 1985-764143	A	19850809		

AB The title dispenser, such as a capsule, has a perforated wall and contains an active ingredient, a material m. at body temp. and an osmotically-active sol. compd. The chamber of a capsule contained a mass made of tetracycline-HCl 1000, **polyethylene** glycol 600 650, **polyethylene** glycol 1000 335, sorbitan monostearate 1.2, and 2,6-di-tert-butylcresol 0.02 mg, as well as a NaCl tablet placed on top of the mass. The wall was made of 90% cellulose acetate butyrate and 10% **polyethylene** glycol 400.

L2 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2001:434830 CAPLUS

DN 135:66028

TI Preparation of stabilized **antimicrobial** systems containing alcohol and metal oxides

IN Jampani, Hanuman; Holly, Thomas F.; Newman, Jerry L.

PA Ethicon, Inc., USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041727	A1	20010614	WO 2000-US34008	20001213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1152741	A1	20011114	EP 2000-984412	20001213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO				

PRAI US 1999-460012 A 19991213

WO 2000-US34008 W 20001213

AB The present invention relates to high alc.-contg. **antimicrobial** compns. with improved stability of appearance and with methods of producing the same. An **antimicrobial** compn. comprises at least .apprx.50% vol./vol. alc., an effective amt. of a hydrophilic oil, an effective amt. of a **cationic antimicrobial** compd., and an effective amt. of a **metal** oxide, e.g., titanium dioxide and **zinc** oxide. The compn. further comprises effective amts. of humectants, phospholipids, and surfactants. A cationic **antimicrobial** compds. are selected from the group consisting of benzalkonium chloride, Me benzethonium chloride, benzethonium chloride, cetrimonium chloride, cetylpyridium chloride, polyhexamethylene biguanide, and chlorhexidine gluconate. For example, an **antimicrobial** gel was prep'd. contg. (by wt.%) water 26.24, EtOH 21.90, PrOH 26.8, glycerol 5.0, propylene glycol 5.0, Plantaren 2000 3.60, Mackam CBS-50G 2.40, benzethonium chloride 1.0, Phospholipid CDM 1.50, PPG-40 diethylmonium chloride (Emcol CC-42) 1.20, hydroxypropyl cellulose 1.10, phenoxyethanol 1.00, glyceryl laurate 1.00, cetrimonium chloride (Varisoft 300) 0.86, isolene 0.50, Lambert Quat AD 0.50, fragrance 0.15, cetylpyridinium 0.10, ZnO 0.10, and Silsoft PEDM 0.05.

L12 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2001:300486 CAPLUS

DN 134:331616

TI Sustained release microspheres based on a carrier protein, a water soluble **polymer** and complexing agents

IN Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia

PA Epic Therapeutics, Inc., USA

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI WO 2001028524	A1	20010426	WO 2000-US28200	20001012	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6458387	B1	20021001	US 1999-420361	19991018	
EP 1223917	A1	20020724	EP 2000-973477	20001012	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
PRAI US 1999-420361	A	19991018			
WO 2000-US28200 W 20001012					
AB	A microsphere compn. for sustained release of therapeutic or diagnostic agents comprises (1) a carrier protein, (2) a water-sol. <b>polymer</b> , (3) a polyanionic polysaccharide as a first complexing agent, and (4) a divalent <b>metal cation</b> (Ca and Mg) as a second complexing agent. The microspheres have a smooth surface that includes a plurality of channel openings that are < 1000 .ANG. in diam. Various drugs were encapsulated into microspheres. For example, microspheres contg. leuprolide acetate were prep'd. using human serum albumin (HSA), dextran sulfate, <b>polyethylene</b> glycol, and polyvinylpyrrolidone. The microspheres were composed of approx. 10% leuprolide acetate, 50% human serum albumin, 20% dextran sulfate and 20% <b>polyethylene</b> glycol/polyvinylpyrrolidone. Similar particles were prep'd. which also included <b>zinc</b> sulfate or caprylic acid, both of which retarded the release of protein and peptide from the microspheres. Also, rifampicin-contg. HSA microspheres were prep'd. with HSA incorporation of 74% and rifampicin incorporation into the particles of > 6.8%. The av. size of the particles was detd. to be 68 nm in diam.				

L12 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2001:434830 CAPLUS

DN 135:66028

TI Preparation of stabilized **antimicrobial** systems containing alcohol and metal oxides

IN Jampani, Hanuman; Holly, Thomas F.; Newman, Jerry L.

PA Ethicon, Inc., USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041727	A1	20010614	WO 2000-US34008	20001213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1152741	A1	20011114	EP 2000-984412	20001213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO				

PRAI US 1999-460012 A 19991213

WO 2000-US34008 W 20001213

L12 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2001:300486 CAPLUS

DN 134:331616

TI Sustained release microspheres based on a carrier protein, a water soluble **polymer** and complexing agents

IN Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia

PA Epic Therapeutics, Inc., USA

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028524	A1	20010426	WO 2000-US28200	20001012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6458387	B1	20021001	US 1999-420361	19991018
	EP 1223917	A1	20020724	EP 2000-973477	20001012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRAI US 1999-420361 A 19991018

WO 2000-US28200 W 20001012

L12 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 2000:98384 CAPLUS

DN 132:141718

TI **Antibiotic** toothpaste containing zeolite and metal ions

IN Barry, John E.; Trogolo, Jeffrey A.

PA B.F. Technologies L.L.C., USA

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006208	A1	20000210	WO 1999-US17089	19990727
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6123925	A	20000926	US 1998-123755	19980727
	AU 9955447	A1	20000221	AU 1999-55447	19990727
	EP 1100445	A1	20010523	EP 1999-941976	19990727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1998-123755 A 19980727

WO 1999-US17089 W 19990727

L12 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1999:492575 CAPLUS

DN 132:61488

TI Metal adsorption of **chitosan** derivatives containing a thiourea group and their **antimicrobial** activities

AU Baba, Y.; Noma, H.; Hoaki, K.

CS Department of Applied Chemistry, Faculty of Engineering, Miyazaki University, Miyazaki, 889-2192, Japan

SO Kichin, Kitosan Kenkyu (1999), 5(2), 142-143

CODEN: KKKEFB; ISSN: 1340-9778

PB Nippon Kichin, Kitosan Gakkai

DT Journal

LA Japanese

L12 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1997:599286 CAPLUS

DN 127:239137

TI **Antimicrobial** compositions useful for medical applications

IN Capelli, Christopher C.

PA USA

SO U.S., 21 pp., Cont.-in-part of U. S. 5,326,567.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5662913	A	19970902	US 1994-268616	19940701
	US 5326567	A	19940705	US 1993-82168	19930628
	US 5607683	A	19970304	US 1995-483815	19950607
	WO 9601119	A1	19960118	WO 1995-US7866	19950628
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,				

TM, TT  
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,  
SN, TD, TG

AU 9529064 A1 19960125 AU 1995-29064 19950628

PRAI US 1991-683436 19910410  
US 1993-82168 19930628  
US 1994-268616 19940701  
WO 1995-US7866 19950628

L12 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1996:164023 CAPLUS

DN 124:212163

TI **Antimicrobial** compositions useful for medical applications

IN Capelli, Christopher C.

PA USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9601119	A1	19960118	WO 1995-US7866	19950628
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

US 5662913 A 19970902 US 1994-268616 19940701

AU 9529064 A1 19960125 AU 1995-29064 19950628

PRAI US 1994-268616 19940701  
US 1991-683436 19910410  
US 1993-82168 19930628  
WO 1995-US7866 19950628

L12 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1977:497756 CAPLUS

DN 87:97756

TI Elementary steps and dynamic aspects of carrier-mediated cation transport  
through membranes: the streptogramin **antibiotics** (group B)

AU Grell, E.; Oberbaeumer, I.; Ruf, H.; Zingsheim, H. P.

CS Max-Planck-Inst. Biophys. Chem., Goettingen, Fed. Rep. Ger.

SO FEBS-Symposium (1977), 42(Biochem. Membr. Transp.), 147-78

CODEN: FEBSDB; ISSN: 0071-4402

DT Journal

LA English

L12 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1975:474016 CAPLUS

DN 83:74016

TI Dynamic properties and membrane activity of ion specific  
**antibiotics**

AU Grell, E.; Funck, Th.; Eggers, F.

CS Max-Planck-Inst. Biophys. Chem., Goettingen, Fed. Rep. Ger.

SO Mol. Mech. Antibiot. Action Protein Biosynth. Membr., Proc. Symp. (1972),  
Meeting Date 1971, 646-85. Editor(s): Munoz, E.; Garcia-Ferrandiz, F.;  
Vazquez, D. Publisher: Elsevier, Amsterdam, Neth.

CODEN: 30QGA7

DT Conference

LA English

L12 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2003 ACS

AN 1969:21199 CAPLUS

DN 70:21199

TI **Antimicrobial** detergent compositions

IN Parran, John J., Jr.

PA Procter and Gamble Co.

SO Fr., 9 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1506349		19671222		
PRAI	US		19650730		

L12 ANSWER 32 OF 36 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2003:32107 BIOSIS

DN PREV200300032107

TI **Antimicrobial** hydrogel forming absorbent polymers and process for making the same.

AU Nakamura, Reiko (1); Hsueh, Kesyin Fugger; Benvegnu, Fernando; Fujioka, Kohtaro

CS (1) Hyogo, Japan Japan

ASSIGNEE: The Procter & Gamble Company

PI US 6476104 November 05, 2002

SO Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 5 2002) Vol. 1264, No. 1, pp. No Pagination.

<http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133.

DT Patent

LA English

L12 ANSWER 35 OF 36 SCISEARCH COPYRIGHT 2003 ISI (R)

AN 97:911468 SCISEARCH

GA The Genuine Article (R) Number: YK072

TI Organometallic complexing agents as carriers in **polymer**-based electrodes

AU Chaniotakis N A (Reprint); Tsagatakis J K; Jurkschat K; Willem R

CS UNIV CRETE, DEPT CHEM, ANALYT CHEM LAB, DEPT SENSOR & BIOSENSOR DEV & APPLICAT, IRAKLION 71409, CRETE, GREECE (Reprint); UNIV DORTMUND, LEHRSTUHL ANORGAN CHEM 2, DORTMUND, GERMANY; FREE UNIV BRUSSELS, HNMR, B-1050 BRUSSELS, BELGIUM

CYA GREECE; GERMANY; BELGIUM

SO REACTIVE & FUNCTIONAL POLYMERS, (NOV 1997) Vol. 34, No. 2-3, pp. 183-188. Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.

ISSN: 1381-5148.

DT Article; Journal

FS PHYS

LA English

REC Reference Count: 16

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L12 ANSWER 36 OF 36 SCISEARCH COPYRIGHT 2003 ISI (R)

AN 91:447564 SCISEARCH

GA The Genuine Article (R) Number: FZ908

TI SELECTIVITIES AND THERMODYNAMIC PARAMETERS OF ALKALI-METAL AND ALKALINE-EARTH-METAL COMPLEXES OF **POLYETHYLENE-GLYCOL** DIMETHYL ETHERS IN METHANOL AND ACETONITRILE

AU VANTRUONG N; NORRIS A R; SHIN H S; BUNCEL E (Reprint); BANNARD R A B; PURDON J G

CS QUEENS UNIV, DEPT CHEM, KINGSTON K7L 3N6, ONTARIO, CANADA; DEF RES ESTAB,  
DIV PROTECT SCI, OTTAWA K1A 0Z4, ONTARIO, CANADA; DEF RES ESTAB SUFFIELD,  
DIV DEF SCI, CB DEF SECT, MEDICINE HAT T1A 8K6, ALBERTA, CANADA  
CYA CANADA  
SO INORGANICA CHIMICA ACTA, (1991) Vol. 184, No. 1, pp. 59-65.  
DT Article; Journal  
FS PHYS  
LA ENGLISH  
REC Reference Count: 69